Paliperidone 相關新聞

← 返回新聞總覽


Paliperidone 目前有 0 則相關新聞報導,預測適應症 20 個。

本頁整合 Paliperidone 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
  • 原適應症:Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older. Invega is indicated for the treatment of schizoaffective disorder in adults.
  • 證據等級:L5
  • 預測適應症(20 個):
    • schizophrenia(100.0%)
    • retinal dystrophy with or without extraocular anomalies(99.9%)
    • schizophreniform disorder(99.9%)
    • myopia X-linked(99.9%)
    • syndromic myopia(99.9%)
    • hydranencephaly (disease)(99.9%)
    • congenital disorder of glycosylation with defective fucosylation(99.9%)
    • myopia 26, X-linked, female-limited(99.9%)
    • psychotic disorder(99.9%)
    • polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis(99.9%)
    • Charcot-Marie-Tooth disease, demyelinating, type 1G(99.9%)
    • atypical glycine encephalopathy(99.8%)
    • treatment-refractory schizophrenia(99.8%)
    • early-onset schizophrenia(99.8%)
    • mental disorder(99.6%)
    • REM sleep behavior disorder(99.5%)
    • psychosexual disorder(99.4%)
    • schizoaffective disorder(99.0%)
    • manic bipolar affective disorder(98.9%)
    • postpartum psychosis(98.9%)

查看完整藥物報告 →

相關新聞(0 則)

目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。

免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.